Hepatitis C – von der individuellen Heilung zur weltweiten Elimination?

Abstract

With the implementation of highly effective direct acting antivirals (DAAs), global control or even elimination of chronic hepatitis C virus (HCV) infection might have come into reach. In fact, DAA therapy leads to complete virus elimination, defined as sustained viral response (SVR), in the vast majority of patients. Moreover, in patients without cirrhosis, the risk of developing HCC after DAA therapy is significantly reduced. For viremic patients who have already received DAA therapy, a distinction must be made between relapse and reinfection. The rate of new infections remains high and many infected individuals are undiagnosed. In order to come closer to the WHO goal of eliminating HCV worldwide by 2030, programs are needed to identify and treat all HCV-infected individuals. Strategies are missing in most countries to achieve this goal. Generic DAA therapies are available in some countries and appear to have similar cure rates compared to those obtained with the original drugs. The high variability of HCV, the numerous strategies of the virus to escape the immune response, and the lack of a suitable small animal model are key hurdles for vaccine development. Currently, the efficacy of two vaccine candidates is being investigated in clinical trials. The development of a protective vaccine is important, despite available therapy, to sustainably reduce the rate of new infections both in developing countries and in people with risk behavior.

Mit der Entwicklung und Zulassung hocheffektiver, direkt antiviral wirksamer Substanzen ist die chronische Hepatitis-C-Virus (HCV)-Infektion zu einer heilbaren Erkrankung geworden. Das Ziel der WHO, sie bis 2030 weltweit zu eliminieren, ist durch diesen immensen Fortschritt theoretisch erreichbar. Der vorliegende Beitrag diskutiert, welche Chancen die neuen Therapien mit sich bringen, wo die Herausforderungen liegen und wie realistisch es ist das ehrgeizige WHO-Ziel zu erreichen.

Schlüsselwörter

antivirale Therapie - Virushepatitis - Impfung - Leberzirrhose - chronische Entzündung

Key words

antiviral therapy - viral hepatitis - vaccination - liver cirrhosis - chronic inflammation

• Literatur

• 1 Choo Q, Kuo G, Weiner A. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362
• 2 Lohmann V, Korner F, Koch J. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113
• 3 Wakita T, Pietschmann T, Kato T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med 2005; 11: 791-796
• 4 Gane EJ, Stedman CA, Hyland RH. et al. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. N Engl J Med 2013; 368: 34-44
• 5 Curry MP, O’Leary JG, Bzowej N. et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373: 2618-2628
• 6 Toyoda H, Kumada T, Kiriyama S. et al. Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy. Clin Infect Dis 2005; 40: e49-e54
• 7 Finkelmeier F, Dultz G, Peiffer KH. et al. Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. Liver Cancer 2018; 7: 190-204
• 8 Simmons B, Saleem J, Hill A. et al. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis 2016; 62: 683-694
• 9 Liang TJ, Ward JW. Hepatitis C in Injection-Drug Users – A Hidden Danger of the Opioid Epidemic. N Engl J Med 2018; 378: 1169-1171
• 10 Walker A, Filke S, Lübke N. et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure. Virol J 2017; 14: 106
• 11 Papatheodoridis GV, Hatzakis A, Cholongitas E. et al. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018; 25: 6-17
• 12 Van Den Berg C, Smit C, Van Brussel G. et al. Full participation in harm reduction programs is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462
• 13 Herder B, Kautz A. Hrsg. Der Eco-Hep Report. In: Leberhilfe Projekt gUG 2016
• 14 Aggarwal R, Chen Q, Goel A. et al. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS ONE 2017; 12: e0176503
• 15 Bartenschlager R, Baumert TF, Bukh J. et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res 2018; 248: 53-62
• 16 Dazert E, Neumann-Haefelin C, Bressanelli S. et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009; 119: 376-386
• 17 Bartenschlager R, Penin F, Lohmann V. et al. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103
• 18 Osburn WO, Fisher BE, Dowd KA. et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-324
• 19 Choo QL, Kuo G, Ralston R. et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-1298
• 20 Swadling L, Capone S, Antrobus RD. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6: 261ra153